title: Primary murine microglia are resistant to nitric oxide inhibition of indoleamine 2,3-dioxygenase.
abstract: Indoleamine 2,3-dioxygenase (IDO) is an intracellular heme-containing enzyme that is activated by proinflammatory cytokines, including interferon-γ (IFNγ), and metabolizes tryptophan along the kynurenine pathway. Activation of murine macrophages induces not only IDO but also nitric oxide synthase (iNOS), and the ensuing production of nitric oxide (NO) inhibits IDO. To determine the sensitivity of primary cultures of murine microglia to NO, microglia were stimulated with recombinant murine IFNγ (1 ng/ml) and lipopolysaccharide (LPS) (10 ng/ml). This combination of IFNγ+LPS synergized to produce maximal amounts of nitrite as early as 16h. Steady-state mRNAs for both iNOS and IDO were significantly increased by IFNγ+LPS at 4h post-treatment, followed by an increase in IDO enzymatic activity at 24h. Murine microglia (>95% CD11b(+)) were pretreated with the iNOS inhibitor, L-NIL hydrochloride, at a dose (30 μM) that completely abrogated production of nitrite. L-NIL had no effect on IDO mRNA at 4h or IDO enzymatic activity at 24h following stimulation with IFNγ+LPS. These data establish that IDO regulation in murine microglia is not restrained by NO, thereby permitting the accumulation of kynurenine and its downstream metabolites in the central nervous system.
authors.affiliation: Integrative Immunology and Behavior Program, Department of Animal Sciences, 227 Edward R Madigan Laboratory, College of ACES, 1201 W Gregory Drive, University of Illinois at Urbana-Champaign, Urbana, IL 61801-3873, USA. crazyfishing08@hotmail.com
authors.forename: Yunxia
authors.initials: Y
authors.lastname: Wang
authors.forename: Marcus A
authors.initials: MA
authors.lastname: Lawson
authors.forename: Keith W
authors.initials: KW
authors.lastname: Kelley
authors.forename: Robert
authors.initials: R
authors.lastname: Dantzer
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D004351:Drug Resistance; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D007371:Interferon-gamma / Q000494:pharmacology; D007737:Kynurenine / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D017628:Microglia / Q000187:drug effects* / Q000201:enzymology*; D009569:Nitric Oxide / Q000494:pharmacology*; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000378:metabolism; D009573:Nitrites / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D008070:Lipopolysaccharides; D009573:Nitrites; D009569:Nitric Oxide; D007737:Kynurenine; D007371:Interferon-gamma; D052247:Nitric Oxide Synthase Type II
references.citation: Annu Rev Immunol. 1997;15:323-50
references.pmid: 9143691
references.citation: Nat Neurosci. 2007 Nov;10(11):1387-94
references.pmid: 17965659
references.citation: Biochemistry. 2006 Jul 18;45(28):8527-38
references.pmid: 16834326
references.citation: Immunol Lett. 2008 Feb 15;116(1):95-102
references.pmid: 18179826
references.citation: Ann N Y Acad Sci. 2007 Dec;1122:35-49
references.pmid: 18077563
references.citation: Nat Rev Immunol. 2009 Jun;9(6):429-39
references.pmid: 19461673
references.citation: Biochem Biophys Res Commun. 2004 Aug 6;320(4):1156-62
references.pmid: 15249210
references.citation: J Immunol. 1997 Jul 1;159(1):419-26
references.pmid: 9200481
references.citation: Nat Rev Neurosci. 2008 Jan;9(1):46-56
references.pmid: 18073775
references.citation: J Neuroimmunol. 2008 Nov 15;204(1-2):101-9
references.pmid: 18703234
references.citation: Biochem Soc Trans. 2009 Apr;37(Pt 2):408-12
references.pmid: 19290871
references.citation: Infect Immun. 2004 May;72(5):2723-30
references.pmid: 15102781
references.citation: Neurosci Lett. 2008 Aug 15;441(1):29-34
references.pmid: 18584961
references.citation: Adv Exp Med Biol. 1996;398:171-5
references.pmid: 8906262
references.citation: Thromb Res. 2000 Nov 1;100(3):223-47
references.pmid: 11108909
references.citation: Infect Immun. 2002 Feb;70(2):779-86
references.pmid: 11796611
references.citation: Med Microbiol Immunol. 1999 Mar;187(3):143-7
references.pmid: 10206145
references.citation: J Immunol. 2006 Jan 1;176(1):372-9
references.pmid: 16365430
references.citation: Brain Behav Immun. 2002 Oct;16(5):596-601
references.pmid: 12401474
references.citation: FASEB J. 1991 Aug;5(11):2516-22
references.pmid: 1907934
references.citation: Biochem Biophys Res Commun. 2009 Nov 13;389(2):229-34
references.pmid: 19715679
references.citation: FASEB J. 1990 Aug;4(11):2906-11
references.pmid: 2165948
references.citation: CNS Neurol Disord Drug Targets. 2007 Dec;6(6):398-410
references.pmid: 18220779
references.citation: J Biol Chem. 1994 May 20;269(20):14457-64
references.pmid: 7514170
references.citation: Curr Biol. 2008 Jun 24;18(12):R506-8
references.pmid: 18579087
references.citation: Annu Rev Immunol. 2009;27:119-45
references.pmid: 19302036
references.citation: Antioxid Redox Signal. 2009 Feb;11(2):193-204
references.pmid: 18715150
references.citation: Glia. 2005 Jan 1;49(1):15-23
references.pmid: 15390107
references.citation: J Neurosci Res. 2004 Aug 15;77(4):540-51
references.pmid: 15264224
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9936-41
references.pmid: 15998743
references.citation: Redox Rep. 1999;4(5):199-220
references.pmid: 10731095
references.citation: J Neurosci. 2008 Nov 12;28(46):12039-51
references.pmid: 19005069
references.citation: FEBS Lett. 2007 Apr 3;581(7):1449-56
references.pmid: 17367785
references.citation: J Neurochem. 2009 May;109 Suppl 1:117-25
references.pmid: 19393017
references.citation: FASEB J. 2005 Aug;19(10):1347-9
references.pmid: 15939737
references.citation: Brain Behav Immun. 2010 Feb;24(2):201-9
references.pmid: 19577630
references.citation: Biochim Biophys Acta. 1999 May 5;1411(2-3):273-89
references.pmid: 10320663
references.citation: Brain Behav Immun. 2002 Oct;16(5):590-5
references.pmid: 12401473